Our finding that NTRK2 activates PI3K/mTOR signaling is consistent with recent studies that NTRK2 promotes lung cancer and chondrosarcoma survival and metastasis by activating PI3K/AKT signaling [39, 40]. Here, AKT1 is linked to lung carcinoma.